Drug resistance beyond extensively drugresistant tuberculosis

Individual patient data meta-analysis

Giovanni Battista Migliori, Giovanni Sotgiu, Neel R. Gandhi, Dennis Falzon, Kathryn DeRiemer, Rosella Centis, Maria Graciela Hollm-Delgado, Domingo Palmero, Carlos Pérez-Guzmán, Mario H. Vargas, Lia D'Ambrosio, Antonio Spanevello, Melissa Bauer, Edward D. Chan, H. Simon Schaaf, Salmaan Keshavjee, Timothy H. Holtz, Dick Menzies, S. Ahuja, D. Ashkin & 53 others M. Avendano, R. Banerjee, J. N. Bayona, M. C. Becerra, A. Benedetti, M. Burgos, C. Y. Chiang, H. Cox, N. H. Dung, D. Enarson, K. Flanagan, J. Flood, L. Garcia-Garcia, R. M. Granich, M. D. Iseman, L. G. Jarlsberg, H. R. Kim, W. J. Koh, J. Lancaster, C. Lange, W. C M De Lange, V. Leimane, C. C. Leung, J. Li, S. P. Mishustin, C. D. Mitnick, M. Narita, P. O'Riordan, M. Pai, S. K. Park, G. Pasvol, J. Pena, A. Ponce-De-Leon, M. I D Quelapio, V. Riekstina, J. Robert, S. Royce, K. J. Seung, L. Shah, T. S. Shim, S. S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, M. J. Strand, P. Tabarsi, T. E. Tupasi, R. Van Altena, M. Van Der Walt, T. S. Van Der Werf, P. Viiklepp, J. Westenhouse, W. W. Yew, J. J. Yim

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

The broadest pattern of tuberculosis (TB) drug resistance for which a consensus definition exists is extensively drug-resistant (XDR)-TB. It is not known if additional drug resistance portends worsened patient outcomes. This study compares treatment outcomes of XDR-TB patients with and without additional resistance in order to explore the need for a new definition. Individual patient data on XDR-TB outcomes were included in a meta-analysis comparing outcomes between XDR alone and three nonmutually exclusive XDR-TB patient groups: XDR plus resistance to all the second-line injectables (sli) and capreomycin and kanamycin/amikacin (XDR+2sli) XDR plus resistance to second-line injectables and to more than one group 4 drug, i.e. ethionamide/protionamide, cycloserine/ terizidone or para-aminosalicylic acid (XDR+sliG4) and XDR+sliG4 plus resistance to ethambutol and/or pyrazinamide (XDR+sliG4EZ). Of 405 XDR-TB cases, 301 were XDR alone, 68 XDR+2sli, 48 XDR+sliG4 and 42 XDR+sliG4EZ. In multivariate analysis, the odds of cure were significantly lower in XDR+2sli (adjusted OR 0.4, 95%CI 0.2- 0.8) compared to XDR alone, while odds of failure and death were higher in all XDR patients with additional resistance (adjusted OR 2.6-2.8). Patients with additional resistance beyond XDR-TB showed poorer outcomes. Limitations in availability, accuracy and reproducibility of current drug susceptibility testing methods preclude the adoption of a useful definition beyond the one currently used for XDR-TB.

Original languageEnglish (US)
Pages (from-to)169-179
Number of pages11
JournalEuropean Respiratory Journal
Volume42
Issue number1
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Drug Resistance
Meta-Analysis
Tuberculosis
Prothionamide
Capreomycin
Extensively Drug-Resistant Tuberculosis
Ethionamide
Aminosalicylic Acid
Cycloserine
Pyrazinamide
Ethambutol
Injections
Kanamycin
Amikacin
Pharmaceutical Preparations
Multivariate Analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Migliori, G. B., Sotgiu, G., Gandhi, N. R., Falzon, D., DeRiemer, K., Centis, R., ... Yim, J. J. (2013). Drug resistance beyond extensively drugresistant tuberculosis: Individual patient data meta-analysis. European Respiratory Journal, 42(1), 169-179. https://doi.org/10.1183/09031936.00136312

Drug resistance beyond extensively drugresistant tuberculosis : Individual patient data meta-analysis. / Migliori, Giovanni Battista; Sotgiu, Giovanni; Gandhi, Neel R.; Falzon, Dennis; DeRiemer, Kathryn; Centis, Rosella; Hollm-Delgado, Maria Graciela; Palmero, Domingo; Pérez-Guzmán, Carlos; Vargas, Mario H.; D'Ambrosio, Lia; Spanevello, Antonio; Bauer, Melissa; Chan, Edward D.; Schaaf, H. Simon; Keshavjee, Salmaan; Holtz, Timothy H.; Menzies, Dick; Ahuja, S.; Ashkin, D.; Avendano, M.; Banerjee, R.; Bayona, J. N.; Becerra, M. C.; Benedetti, A.; Burgos, M.; Chiang, C. Y.; Cox, H.; Dung, N. H.; Enarson, D.; Flanagan, K.; Flood, J.; Garcia-Garcia, L.; Granich, R. M.; Iseman, M. D.; Jarlsberg, L. G.; Kim, H. R.; Koh, W. J.; Lancaster, J.; Lange, C.; De Lange, W. C M; Leimane, V.; Leung, C. C.; Li, J.; Mishustin, S. P.; Mitnick, C. D.; Narita, M.; O'Riordan, P.; Pai, M.; Park, S. K.; Pasvol, G.; Pena, J.; Ponce-De-Leon, A.; Quelapio, M. I D; Riekstina, V.; Robert, J.; Royce, S.; Seung, K. J.; Shah, L.; Shim, T. S.; Shin, S. S.; Shiraishi, Y.; Sifuentes-Osornio, J.; Strand, M. J.; Tabarsi, P.; Tupasi, T. E.; Van Altena, R.; Van Der Walt, M.; Van Der Werf, T. S.; Viiklepp, P.; Westenhouse, J.; Yew, W. W.; Yim, J. J.

In: European Respiratory Journal, Vol. 42, No. 1, 01.07.2013, p. 169-179.

Research output: Contribution to journalArticle

Migliori, GB, Sotgiu, G, Gandhi, NR, Falzon, D, DeRiemer, K, Centis, R, Hollm-Delgado, MG, Palmero, D, Pérez-Guzmán, C, Vargas, MH, D'Ambrosio, L, Spanevello, A, Bauer, M, Chan, ED, Schaaf, HS, Keshavjee, S, Holtz, TH, Menzies, D, Ahuja, S, Ashkin, D, Avendano, M, Banerjee, R, Bayona, JN, Becerra, MC, Benedetti, A, Burgos, M, Chiang, CY, Cox, H, Dung, NH, Enarson, D, Flanagan, K, Flood, J, Garcia-Garcia, L, Granich, RM, Iseman, MD, Jarlsberg, LG, Kim, HR, Koh, WJ, Lancaster, J, Lange, C, De Lange, WCM, Leimane, V, Leung, CC, Li, J, Mishustin, SP, Mitnick, CD, Narita, M, O'Riordan, P, Pai, M, Park, SK, Pasvol, G, Pena, J, Ponce-De-Leon, A, Quelapio, MID, Riekstina, V, Robert, J, Royce, S, Seung, KJ, Shah, L, Shim, TS, Shin, SS, Shiraishi, Y, Sifuentes-Osornio, J, Strand, MJ, Tabarsi, P, Tupasi, TE, Van Altena, R, Van Der Walt, M, Van Der Werf, TS, Viiklepp, P, Westenhouse, J, Yew, WW & Yim, JJ 2013, 'Drug resistance beyond extensively drugresistant tuberculosis: Individual patient data meta-analysis', European Respiratory Journal, vol. 42, no. 1, pp. 169-179. https://doi.org/10.1183/09031936.00136312
Migliori, Giovanni Battista ; Sotgiu, Giovanni ; Gandhi, Neel R. ; Falzon, Dennis ; DeRiemer, Kathryn ; Centis, Rosella ; Hollm-Delgado, Maria Graciela ; Palmero, Domingo ; Pérez-Guzmán, Carlos ; Vargas, Mario H. ; D'Ambrosio, Lia ; Spanevello, Antonio ; Bauer, Melissa ; Chan, Edward D. ; Schaaf, H. Simon ; Keshavjee, Salmaan ; Holtz, Timothy H. ; Menzies, Dick ; Ahuja, S. ; Ashkin, D. ; Avendano, M. ; Banerjee, R. ; Bayona, J. N. ; Becerra, M. C. ; Benedetti, A. ; Burgos, M. ; Chiang, C. Y. ; Cox, H. ; Dung, N. H. ; Enarson, D. ; Flanagan, K. ; Flood, J. ; Garcia-Garcia, L. ; Granich, R. M. ; Iseman, M. D. ; Jarlsberg, L. G. ; Kim, H. R. ; Koh, W. J. ; Lancaster, J. ; Lange, C. ; De Lange, W. C M ; Leimane, V. ; Leung, C. C. ; Li, J. ; Mishustin, S. P. ; Mitnick, C. D. ; Narita, M. ; O'Riordan, P. ; Pai, M. ; Park, S. K. ; Pasvol, G. ; Pena, J. ; Ponce-De-Leon, A. ; Quelapio, M. I D ; Riekstina, V. ; Robert, J. ; Royce, S. ; Seung, K. J. ; Shah, L. ; Shim, T. S. ; Shin, S. S. ; Shiraishi, Y. ; Sifuentes-Osornio, J. ; Strand, M. J. ; Tabarsi, P. ; Tupasi, T. E. ; Van Altena, R. ; Van Der Walt, M. ; Van Der Werf, T. S. ; Viiklepp, P. ; Westenhouse, J. ; Yew, W. W. ; Yim, J. J. / Drug resistance beyond extensively drugresistant tuberculosis : Individual patient data meta-analysis. In: European Respiratory Journal. 2013 ; Vol. 42, No. 1. pp. 169-179.
@article{74c2ff9d47de45ffb6e0ff55c797bd9d,
title = "Drug resistance beyond extensively drugresistant tuberculosis: Individual patient data meta-analysis",
abstract = "The broadest pattern of tuberculosis (TB) drug resistance for which a consensus definition exists is extensively drug-resistant (XDR)-TB. It is not known if additional drug resistance portends worsened patient outcomes. This study compares treatment outcomes of XDR-TB patients with and without additional resistance in order to explore the need for a new definition. Individual patient data on XDR-TB outcomes were included in a meta-analysis comparing outcomes between XDR alone and three nonmutually exclusive XDR-TB patient groups: XDR plus resistance to all the second-line injectables (sli) and capreomycin and kanamycin/amikacin (XDR+2sli) XDR plus resistance to second-line injectables and to more than one group 4 drug, i.e. ethionamide/protionamide, cycloserine/ terizidone or para-aminosalicylic acid (XDR+sliG4) and XDR+sliG4 plus resistance to ethambutol and/or pyrazinamide (XDR+sliG4EZ). Of 405 XDR-TB cases, 301 were XDR alone, 68 XDR+2sli, 48 XDR+sliG4 and 42 XDR+sliG4EZ. In multivariate analysis, the odds of cure were significantly lower in XDR+2sli (adjusted OR 0.4, 95{\%}CI 0.2- 0.8) compared to XDR alone, while odds of failure and death were higher in all XDR patients with additional resistance (adjusted OR 2.6-2.8). Patients with additional resistance beyond XDR-TB showed poorer outcomes. Limitations in availability, accuracy and reproducibility of current drug susceptibility testing methods preclude the adoption of a useful definition beyond the one currently used for XDR-TB.",
author = "Migliori, {Giovanni Battista} and Giovanni Sotgiu and Gandhi, {Neel R.} and Dennis Falzon and Kathryn DeRiemer and Rosella Centis and Hollm-Delgado, {Maria Graciela} and Domingo Palmero and Carlos P{\'e}rez-Guzm{\'a}n and Vargas, {Mario H.} and Lia D'Ambrosio and Antonio Spanevello and Melissa Bauer and Chan, {Edward D.} and Schaaf, {H. Simon} and Salmaan Keshavjee and Holtz, {Timothy H.} and Dick Menzies and S. Ahuja and D. Ashkin and M. Avendano and R. Banerjee and Bayona, {J. N.} and Becerra, {M. C.} and A. Benedetti and M. Burgos and Chiang, {C. Y.} and H. Cox and Dung, {N. H.} and D. Enarson and K. Flanagan and J. Flood and L. Garcia-Garcia and Granich, {R. M.} and Iseman, {M. D.} and Jarlsberg, {L. G.} and Kim, {H. R.} and Koh, {W. J.} and J. Lancaster and C. Lange and {De Lange}, {W. C M} and V. Leimane and Leung, {C. C.} and J. Li and Mishustin, {S. P.} and Mitnick, {C. D.} and M. Narita and P. O'Riordan and M. Pai and Park, {S. K.} and G. Pasvol and J. Pena and A. Ponce-De-Leon and Quelapio, {M. I D} and V. Riekstina and J. Robert and S. Royce and Seung, {K. J.} and L. Shah and Shim, {T. S.} and Shin, {S. S.} and Y. Shiraishi and J. Sifuentes-Osornio and Strand, {M. J.} and P. Tabarsi and Tupasi, {T. E.} and {Van Altena}, R. and {Van Der Walt}, M. and {Van Der Werf}, {T. S.} and P. Viiklepp and J. Westenhouse and Yew, {W. W.} and Yim, {J. J.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1183/09031936.00136312",
language = "English (US)",
volume = "42",
pages = "169--179",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Drug resistance beyond extensively drugresistant tuberculosis

T2 - Individual patient data meta-analysis

AU - Migliori, Giovanni Battista

AU - Sotgiu, Giovanni

AU - Gandhi, Neel R.

AU - Falzon, Dennis

AU - DeRiemer, Kathryn

AU - Centis, Rosella

AU - Hollm-Delgado, Maria Graciela

AU - Palmero, Domingo

AU - Pérez-Guzmán, Carlos

AU - Vargas, Mario H.

AU - D'Ambrosio, Lia

AU - Spanevello, Antonio

AU - Bauer, Melissa

AU - Chan, Edward D.

AU - Schaaf, H. Simon

AU - Keshavjee, Salmaan

AU - Holtz, Timothy H.

AU - Menzies, Dick

AU - Ahuja, S.

AU - Ashkin, D.

AU - Avendano, M.

AU - Banerjee, R.

AU - Bayona, J. N.

AU - Becerra, M. C.

AU - Benedetti, A.

AU - Burgos, M.

AU - Chiang, C. Y.

AU - Cox, H.

AU - Dung, N. H.

AU - Enarson, D.

AU - Flanagan, K.

AU - Flood, J.

AU - Garcia-Garcia, L.

AU - Granich, R. M.

AU - Iseman, M. D.

AU - Jarlsberg, L. G.

AU - Kim, H. R.

AU - Koh, W. J.

AU - Lancaster, J.

AU - Lange, C.

AU - De Lange, W. C M

AU - Leimane, V.

AU - Leung, C. C.

AU - Li, J.

AU - Mishustin, S. P.

AU - Mitnick, C. D.

AU - Narita, M.

AU - O'Riordan, P.

AU - Pai, M.

AU - Park, S. K.

AU - Pasvol, G.

AU - Pena, J.

AU - Ponce-De-Leon, A.

AU - Quelapio, M. I D

AU - Riekstina, V.

AU - Robert, J.

AU - Royce, S.

AU - Seung, K. J.

AU - Shah, L.

AU - Shim, T. S.

AU - Shin, S. S.

AU - Shiraishi, Y.

AU - Sifuentes-Osornio, J.

AU - Strand, M. J.

AU - Tabarsi, P.

AU - Tupasi, T. E.

AU - Van Altena, R.

AU - Van Der Walt, M.

AU - Van Der Werf, T. S.

AU - Viiklepp, P.

AU - Westenhouse, J.

AU - Yew, W. W.

AU - Yim, J. J.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The broadest pattern of tuberculosis (TB) drug resistance for which a consensus definition exists is extensively drug-resistant (XDR)-TB. It is not known if additional drug resistance portends worsened patient outcomes. This study compares treatment outcomes of XDR-TB patients with and without additional resistance in order to explore the need for a new definition. Individual patient data on XDR-TB outcomes were included in a meta-analysis comparing outcomes between XDR alone and three nonmutually exclusive XDR-TB patient groups: XDR plus resistance to all the second-line injectables (sli) and capreomycin and kanamycin/amikacin (XDR+2sli) XDR plus resistance to second-line injectables and to more than one group 4 drug, i.e. ethionamide/protionamide, cycloserine/ terizidone or para-aminosalicylic acid (XDR+sliG4) and XDR+sliG4 plus resistance to ethambutol and/or pyrazinamide (XDR+sliG4EZ). Of 405 XDR-TB cases, 301 were XDR alone, 68 XDR+2sli, 48 XDR+sliG4 and 42 XDR+sliG4EZ. In multivariate analysis, the odds of cure were significantly lower in XDR+2sli (adjusted OR 0.4, 95%CI 0.2- 0.8) compared to XDR alone, while odds of failure and death were higher in all XDR patients with additional resistance (adjusted OR 2.6-2.8). Patients with additional resistance beyond XDR-TB showed poorer outcomes. Limitations in availability, accuracy and reproducibility of current drug susceptibility testing methods preclude the adoption of a useful definition beyond the one currently used for XDR-TB.

AB - The broadest pattern of tuberculosis (TB) drug resistance for which a consensus definition exists is extensively drug-resistant (XDR)-TB. It is not known if additional drug resistance portends worsened patient outcomes. This study compares treatment outcomes of XDR-TB patients with and without additional resistance in order to explore the need for a new definition. Individual patient data on XDR-TB outcomes were included in a meta-analysis comparing outcomes between XDR alone and three nonmutually exclusive XDR-TB patient groups: XDR plus resistance to all the second-line injectables (sli) and capreomycin and kanamycin/amikacin (XDR+2sli) XDR plus resistance to second-line injectables and to more than one group 4 drug, i.e. ethionamide/protionamide, cycloserine/ terizidone or para-aminosalicylic acid (XDR+sliG4) and XDR+sliG4 plus resistance to ethambutol and/or pyrazinamide (XDR+sliG4EZ). Of 405 XDR-TB cases, 301 were XDR alone, 68 XDR+2sli, 48 XDR+sliG4 and 42 XDR+sliG4EZ. In multivariate analysis, the odds of cure were significantly lower in XDR+2sli (adjusted OR 0.4, 95%CI 0.2- 0.8) compared to XDR alone, while odds of failure and death were higher in all XDR patients with additional resistance (adjusted OR 2.6-2.8). Patients with additional resistance beyond XDR-TB showed poorer outcomes. Limitations in availability, accuracy and reproducibility of current drug susceptibility testing methods preclude the adoption of a useful definition beyond the one currently used for XDR-TB.

UR - http://www.scopus.com/inward/record.url?scp=84880158505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880158505&partnerID=8YFLogxK

U2 - 10.1183/09031936.00136312

DO - 10.1183/09031936.00136312

M3 - Article

VL - 42

SP - 169

EP - 179

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

ER -